SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Iossa Domenico)
 

Sökning: WFRF:(Iossa Domenico) > Colistin plus merop...

Colistin plus meropenem for carbapenem-resistant Gram-negative infections : in vitro synergism is not associated with better clinical outcomes

Nutman, Amir (författare)
Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel.;Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
Lellouche, Jonathan (författare)
Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel.
Temkin, Elizabeth (författare)
Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel.
visa fler...
Daikos, George (författare)
Laikon Gen Hosp, Dept Med 1, Athens, Greece.;Natl & Kapodistrian Univ Athens, Athens, Greece.
Skiada, Anna (författare)
Laikon Gen Hosp, Dept Med 1, Athens, Greece.;Natl & Kapodistrian Univ Athens, Athens, Greece.
Durante-Mangoni, Emanuele (författare)
Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy.;AORN Colli Monaldi Hosp, Naples, Italy.
Dishon-Benattar, Yael (författare)
Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel.;Univ Haifa, Cheryl Spencer Inst Nursing Res, Haifa, Israel.
Bitterman, Roni (författare)
Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel.
Yahav, Dafna (författare)
Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.;Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel.
Daitch, Vered (författare)
Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.;Beilinson Med Ctr, Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel.
Bernardo, Mariano (författare)
Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy.;AORN Colli Monaldi Hosp, Naples, Italy.
Iossa, Domenico (författare)
Univ Campania Luigi Vanvitelli, Dept Precis Med, Naples, Italy.;AORN Colli Monaldi Hosp, Naples, Italy.
Zusman, Oren (författare)
Beilinson Med Ctr, Dept Med E, Rabin Med Ctr, Peta Tikva, Israel.
Friberg, Lena (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Mouton, Johan W. (författare)
Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands.
Theuretzbacher, Ursula (författare)
Ctr Antiinfect Agents, Vienna, Austria.
Leibovici, Leonard (författare)
Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.;Beilinson Med Ctr, Dept Med E, Rabin Med Ctr, Peta Tikva, Israel.
Paul, Mical (författare)
Rambam Hlth Care Campus, Inst Infect Dis, Haifa, Israel.;Techion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.
Carmeli, Yehuda (författare)
Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel.;Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
visa färre...
Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel;Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel. Tel Aviv Med Ctr & Sch Med, Natl Inst Infect Control & Antibiot Resistance, Tel Aviv, Israel. (creator_code:org_t)
Elsevier BV, 2020
2020
Engelska.
Ingår i: Clinical Microbiology and Infection. - : Elsevier BV. - 1198-743X .- 1469-0691. ; 26:9, s. 1185-1191
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • ObjectivesIn vitro models showing synergism between polymyxins and carbapenems support combination treatment for carbapenem-resistant Gram-negative (CRGN) infections. We tested the association between the presence of in vitro synergism and clinical outcomes in patients treated with colistin plus meropenem.MethodsThis was a secondary analysis of AIDA, a randomized controlled trial comparing colistin with colistin–meropenem for severe CRGN infections. We tested in vitro synergism using a checkerboard assay. Based on the fractional inhibitory concentration (ΣFIC) index for each colistin–meropenem combination, we categorized results as synergistic, antagonistic or additive/indifferent. The primary outcome was clinical failure at 14 days. Secondary outcomes were 14- and 28-day mortality and microbiological failure.ResultsThe sample included 171 patients with infections caused by carbapenem-resistant Acinetobacter baumannii (n = 131), Enterobacteriaceae (n = 37) and Pseudomonas aeuruginosa (n = 3). In vitro testing showed synergism for 73 isolates, antagonism for 20 and additivism/indifference for 78. In patients who received any colistin plus meropenem, clinical failure at 14 days was 59/78 (75.6%) in the additivism/indifference group (reference category), 54/73 (74.0%) in the synergism group (adjusted odds ratio (aOR) 0.76, 95% CI 0.31–1.83), and 11/20 (55%) in the antagonism group (aOR 0.77, 95% CI 0.22–2.73). There was no significant difference between groups for any secondary outcome. Comparing the synergism group to patients treated with colistin monotherapy, synergism was not protective against 14-day clinical failure (aOR 0.52, 95% CI 0.26–1.04) or 14-day mortality (aOR1.09, 95% CI 0.60–1.96).DiscussionIn vitro synergism between colistin and meropenem via checkerboard method did not translate into clinical benefit.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Nyckelord

Carbapenem resistance
Checkerboard assay
Colistin
Combination treatment
Gram-negative infections synergism

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy